Amgen, TScan Therapeutics Set Crohn's Disease Collaboration
09 Maio 2023 - 10:48AM
Dow Jones News
By Colin Kellaher
Amgen on Tuesday said it has signed onto a multi-year
collaboration with clinical-stage biopharmaceutical company TScan
Therapeutics targeting the chronic inflammatory bowel disorder
Crohn's disease.
Amgen said it would make a $30 million upfront payment to
Waltham, Mass.-based TScan, which is also eligible for more than
$500 million in milestone payments, along with royalties on product
sales.
Amgen, a Thousand Oaks, Calif., biotechnology company, said it
would use TScan's TargetScan discovery platform to identify the
antigens recognized by T cells in patients with Crohn's
disease.
Amgen said it plans to evaluate a variety of modalities to
create therapeutics based on targets discovered by TScan, adding
that it would retain all global development and commercial
rights.
Amgen said it also has an option to expand the collaboration to
the chronic inflammatory bowel disease ulcerative colitis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 09, 2023 09:33 ET (13:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Amgen (NASDAQ:AMGN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
